Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Robert Coffin"'
Autor:
Anna Olsson-Brown, Mohammed M. Milhem, P.K. Bommareddy, Andrea Pirzkall, S. Samakoglu, Francesca Aroldi, L. Menezes, Adel Samson, Jiaxin Niu, Robert Coffin, Jason Chesney, Ari M. Vanderwalde, Scott Baum, Brendan D. Curti, Mark R. Middleton, T.L. Bowles, Terence Duane Rhodes, Joseph J. Sacco, K.J. Harrington, Douglas Earl Laux
Publikováno v:
Annals of Oncology. 32:S903-S904
Publikováno v:
Oncolytic Virotherapy
Oncolytic viruses that selectively lyse tumor cells with minimal damage to normal cells are a new area of therapeutic development in oncology. An attenuated herpesvirus encoding the granulocyte-macrophage colony stimulating factor (GM-CSF), known as
Autor:
Howard Goldsweig, Thomas Amatruda, Howard L. Kaufman, Tony Reid, Mike Nemunaitis, Neil Senzer, Gregory Daniels, John A. Glaspy, Tracey Marshall, John Nemunaitis, Rene Gonzalez, Colin Love, Eric D. Whitman, Robert Coffin, Kevin J. Harrington
Publikováno v:
Journal of Clinical Oncology. 27:5763-5771
Purpose Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage colony-stimulating factor (GM-CSF) in stages IIIc and IV disease. Patients and Methods Trea
Autor:
Jason Chesney, Kevin J. Harrington, Kate Liu, Mark Shilkrut, S. Fourie, Frances A. Collichio, Lydia Dreosti, N.M. Steven, Robert Coffin, John Nemunaitis, Robert H.I. Andtbacka, Ai Li, Thomas Amatruda, Merrick I. Ross, Howard L. Kaufman
Publikováno v:
Annals of Oncology. 25:iv382
Aim: T-VEC is an HSV-1-derived oncolytic immunotherapy designed to selectively replicate in tumors and produce GM-CSF to enhance systemic antitumor immune responses. Compared to GM-CSF alone, T-VEC significantly improved durable response rate (DRR; p
Autor:
N. Senzer, Robert Coffin, John A. Glaspy, Gregory Daniels, Mike Nemunaitis, Howard Goldsweig, Howard L. Kaufman, Thomas Amatruda, John Nemunaitis
Publikováno v:
Journal of Clinical Oncology. 27:9035-9035
9035 Background: OncoVEXGM-CSF is a an oncolytic HSV, encoding GM-CSF . We recently completed a phase II trial involving 50 advanced melanoma patients (stage IIIc and IV) with at least one injection accessible lesion, including by ultrasound. Methods
Autor:
Colin Love, Agnieszka Michael, J. C. Hu, Hardev Pandha, Robert Coffin, Neil Steven, C. Coombes, C. J. Davis, Nicholas D. James, Jan Steiner
Publikováno v:
Journal of Clinical Oncology. 23:3099-3099
3099 OncoVEXGM-CSF is a second generation oncolytic HSV expressing GM-CSF. Deletion of ICP34.5 provides tumour selectivity. Oncolytic potency is increased using a clinical virus strain, and by expr...